GELS
Gelteq Limited Ordinary Shares
NASDAQ: GELS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$0.66
+2.00% today
Updated 2026-05-01
Market cap
$6.91M
P/E ratio
—
P/S ratio
16.72x
EPS (TTM)
$-0.52
Dividend yield
—
52W range
$1 – $4
Volume
0.0M
Gelteq Limited Ordinary Shares (GELS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $147536.00 | $79843.00 | $0.00 | $165645.00 |
| Revenue growth (YoY) | — | — | — | -45.9% | -100.0% | — |
| Cost of revenue | — | $0.00 | $94874.00 | $48925.00 | $0.00 | — |
| Gross profit | — | $0.00 | $52662.00 | $30918.00 | $0.00 | $165645.00 |
| Gross margin | — | — | 35.7% | 38.7% | — | 100.0% |
| R&D | $342357.00 | $277055.00 | $529017.00 | $665035.00 | $276057.00 | $628606.00 |
| SG&A | $168688.00 | $450954.00 | $1.48M | $1.53M | $1.25M | $2.02M |
| Operating income | — | $-647624.00 | $-3.19M | $-3.10M | $-2.95M | $-5.50M |
| Operating margin | — | — | -2164.4% | -3885.3% | — | -3317.7% |
| EBITDA | $-527233.00 | $-589679.00 | $-1.98M | $-1.88M | $-1.75M | $-3.53M |
| EBITDA margin | — | — | -1341.5% | -2349.9% | — | -2129.8% |
| EBIT | $-529620.00 | $-647624.00 | $-3.19M | $-3.10M | $-2.96M | $-4.75M |
| Interest expense | — | $1297.00 | $174503.00 | $403521.00 | $585120.00 | $1.89M |
| Income tax | $-154033.00 | — | — | — | — | — |
| Effective tax rate | 29.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-375587.00 | $-648921.00 | $-3.37M | $-3.51M | $-3.55M | $-6.65M |
| Net income growth (YoY) | — | -72.8% | -419.2% | -4.1% | -1.1% | -87.4% |
| Profit margin | — | — | -2283.4% | -4391.4% | — | -4011.9% |